NCT01497262 - Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Multiple Sclerosis

Interventions

DRUG

Fingolimod

Fingolimod will be supplied as 0.5mg capsules in bottles of 35.

Trial Locations (29)

11

Novartis Investigative Site, Jesus Maria

27

Novartis Investigative Site, San Isidro

1425

Novartis Investigative Site, Caba

4000

Novartis Investigative Site, San Miguel de Tucumán

10700

Novartis Investigative Site, Mexico City

10990

Novartis Investigative Site, George Town

11942

Novartis Investigative Site, Amman

22110

Novartis Investigative Site, Irbid

50586

Novartis Investigative Site, Kuala Lumpur

59100

Novartis Investigative Site, Kuala Lumpur

64060

Novartis Investigative Site, Monterrey

66480

Novartis Investigative Site, San Nicolás de los Garza

78240

Novartis Investigative Site, San Luis Potosí City

110111

Novartis Investigative Site, Bogotá

M5507XAD

Novartis Investigative Site, Villa Nueva

A4400ANG

Novartis Investigative Site, Salta

A4400BKZ

Novartis Investigative Site, Salta

T4000DPB

Novartis Investigative Site, San Miguel de Tucumán

X5004CDT

Novartis Investigative Site, Córdoba

20270-004

Novartis Investigative Site, Rio de Janeiro

21941-590

Novartis Investigative Site, Rio de Janeiro

90610-000

Novartis Investigative Site, Porto Alegre

Unknown

Novartis Investigative Site, Barranquilla

Novartis Investigative Site, Bogotá

Novartis Investigative Site, Santiago de Cali

Novartis Investigative Site, Panama City

00000

Novartis Investigative Site, Bogotá

06700

Novartis Investigative Site, Mexico City

04

Novartis Investigative Site, La Perla